Amorepacific Corporation

Other

Kwanghyun Shin

Wonkyung Cho

Jaehong Park

Youngho Park

Byoung Young Woo

Miyoung Park

Joonho Choi

Jong Hwa Roh

Eunsil Park

Kiwha Lee

Min Soo Kim

Yong Deog Hong

Jinoh Chung

Chang Soon Choi

Kyoungmi Jung

Gyeyoung Choi

Hyunjin Nam

Jihae Lee

Changkeun Lee

Sungwon Yi

Seongjin Park

Byungyoung Kang

Taehong Shin

Seunghwan Yi

Changman Park

Taekjin Oh

Eun Sol Ha

Seongjin Lim

Dongwook Lee

Danin Jeon

An intraocular pressure measurement system includes an ultrasound transmitter configured to generate a first driving signal and a second driving signal, a probe comprising a plurality of transducers, the probe configured to generate a first ultrasound signal based on the first driving signal, generate a second ultrasound signal based on the second driving signal, and irradiate the first ultrasound signal and the second ultrasound signal onto an eyeball, an ultrasound receiver configured to receive an echo signal, which is the reflected second ultrasound signal, through the probe, and generate an ultrasound data based on the echo signal; and an image processing device configured to measure an intraocular pressure of an internal structure of the eyeball.

System for measuring intraocular pressure

One aspect of the present disclosure relates to a pharmaceutical composition, containing (R)-N-[1-(3,5-difluoro-4-methanesulfonylamino-phenyl)-ethyl]-3-(2-propyl-6-trifluoromethyl-pyridin-3-yl)-acrylamide as a first ingredient and containing a vinylpyrrolidone-based polymer as a second ingredient. The composition of one aspect of the present disclosure has a formulation characteristic in which the crystal formation of a compound represented by chemical formula 1 is delayed for a long time.

Pharmaceutical composition containing (R)-N-[1-(3,5-difluoro-4-methanesulfonylamino-phenyl)-ethyl]-3-(2-propyl-6-trifluoromethylpyridin-3-yl)-acrylamide and method for inhibiting crystal formation thereof

One aspect of the present disclosure relates to a sol-gel composition enabling reversible sol-gel transition and, more specifically, to a sol-gel composition of which the viscosity changes by external physical force so that reversible sol-gel transition is performed.

Topical sol-gel composition for the treatment of dermatitis

Disclosed is a method for preventing or treating atopic dermatitis using TRPV1 receptor antagonist. More specifically, it may be possible to prevent and/or treat the atopic dermatitis without any side effects such as an increase in body temperature, epidermal atrophy, and the like by percutaneously administrating a composition for external use on the skin containing the TRPV1 receptor antagonist.

Composition for preventing or treating atopic dermatitis

Shown are a particulate processed product of tea and a method for preparing the same. The particulate processed product of tea has a sphericity Svalue of a particle corresponding to 10% cumulative subdistribution in cumulative distribution measured for the sphericity of tea particles of 0.68 or greater. The processed product of tea is convenient to drink because it is readily wetted and dispersed in water. In addition, it can be easily packaged and used due to a low angle of repose and thus excellent flowability.

Processed products of tea and method for manufacturing the same

The present disclosure shows a particulate processed product of tea with quick dispersibility in water and a method for manufacturing a particulate processed product of tea. The processed product of tea comprises 20% by weight or less of fine powders having a particle diameter of 75 &#x3bc;m or less based on the total weight of the tea particles. The manufacturing method comprises the step of manufacturing tea particles using a fluid-bed rotor granulator having a rotor disc. The processed product of tea has quick wettability and dispersibility in water and thus is easy to drink. Also, the processed product of tea has a low angle of repose and thus has excellent flowability, so that it is easy to pack and use.

Processed products of tea with quick dispersibility in water and method for manufacturing processed products of tea

Disclosed is a method for preventing or treating sleep disorders using TRPV1 receptor antagonist, (R)&#x2014;N-[1-(3,5-difluoro-4-methanesulfonylamino-phenyl)-ethyl]-3-(2-propyl-6-trifluoromethyl-pyridin-3-yl)-acrylamide. The method of the present invention can effectively and safely prevent or treat sleep disorders accompanying pruritus caused by atopic dermatitis.

Composition for preventing or treating sleep disorders

The present invention includes a flexible main body; a drug layer attached to a bottom surface of the main body and formed of an additive mixed with a drug and formed of anti-inflammatory analgesic drugs; a vibrating module attached on a top surface of the main body and including a vibration motor and a battery; and a plurality of legs installed along the perimeter of the main body and being adhesive. Through this configuration in which the main body is formed of a flexible material, and the plurality of legs are adhesive and are attached along the perimeter of the main body, the vibrating stimulus pad may be easily attached on an unwell body region to which attachment is difficult such as a joint region.

Vibrating stimulus pad

Growing community of inventors

Yongin-si, South Korea

Kwanghyun Shin